These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Titulaer MJ; Lang B; Verschuuren JJ Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130 [TBL] [Abstract][Full Text] [Related]
30. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. Lang B; Newsom-Davis J; Prior C; Wray D J Physiol; 1983 Nov; 344():335-45. PubMed ID: 6655585 [TBL] [Abstract][Full Text] [Related]
32. Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate. Fukuoka T; Engel AG; Lang B; Newsom-Davis J; Vincent A Ann Neurol; 1987 Aug; 22(2):200-11. PubMed ID: 3310854 [TBL] [Abstract][Full Text] [Related]
34. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Buchwald B; Ahangari R; Weishaupt A; Toyka KV Muscle Nerve; 2005 Apr; 31(4):487-94. PubMed ID: 15685615 [TBL] [Abstract][Full Text] [Related]
35. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome. Takamori M Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662 [TBL] [Abstract][Full Text] [Related]
36. Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones. Fukuoka T; Engel AG; Lang B; Newsom-Davis J; Prior C; Wray DW Ann Neurol; 1987 Aug; 22(2):193-9. PubMed ID: 3662451 [TBL] [Abstract][Full Text] [Related]
37. [Lambert-Eaton myasthenic syndrome]. Motomura M; Fukuda T Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145 [TBL] [Abstract][Full Text] [Related]